logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
H

Heng Mei

Huazhong University of Science and Technology
H指数:34
被引数:7,432

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial

皮下注射Efgartigimod PH20在成人原发性免疫性血小板减少症中的有效性和安全性（ADVANCE SC）：一项多中心、随机、双盲、安慰剂对照的III期临床试验

American Journal of Hematology
IF9.9
2026-04-060
OAAI
Nichola Cooper; Catherine M. Broome; Yoshitaka Miyakawa; Vickie McDonald; Hanny Al-Samkari; Abderrahim Khelif; Spero R. Cataland; Wilma Barcellini; Renchi Yang; Heng Mei; Filip Matthijssens; Anna Hultberg; Giorgia Ciurlia; Domenica Gandini; Jaume Ayguasanosa; Kristof De Beuf; Ségolène Pastouret; Waleed Ghanima; Francesco Rodeghiero; James B. Bussel; the ADVANCE SC Investigator Trial Group
Combined FXIII-C3 autoantibodies elicit bleeding and complement dysfunction in autoimmune FXIII deficiency

联合FXIII-C3自身抗体可引发出血和补体功能障碍，导致自身免疫性FXIII缺乏症

Journal of Clinical Investigation
IF13.6
2026-02-020
OA
Luo, Shanshan; Deng, Jun; Liu, Yue; Xiong, Lv; Wang, Wanting; Wang, Chaofan; Cai, Yaohua; Ding, Yajie; Fayed, Bahgat; Cheng, Zhipeng; Zhang, Lu; Zhang, Min; Fang, Jun; Zhang, Gensheng; Zhu, Rui; Jiang, Haiqiang; Li, Yunlun; Huang, Kun; Cheng, Xiang; Tang, Liang, V; Sun, Chunyan; Mei, Heng; Zipfel, Peter F.; Wang, Huafang; Wang, Yadan; Hu, Desheng; Hu, Yu
Phase 2 Study of Relmacabtagene Autoleucel (CD19 CAR-T) for Relapsed/Refractory Mantle Cell Lymphoma in Chinese Adults

II期研究：评估Relmacabtagene autoleucel（CD19 CAR-T）治疗中国成人复发/难治性套细胞淋巴瘤的疗效

Blood Advances
IF7.1
2025-11-100
OAAI
Yan Xie; Ke-Shu Zhou; Lan-Fang Li; Ai-Bin Liang; Heng Mei; De-hui Zou; Wen-Yu Li; Jie Jin; Zheng-Ming Jin; Hong-Mei Jing; Hai-Yan Yang; Tong Chen; Hui-Qiang Huang; Peng-Cheng He; Jun-Ning Cao; Zhen Xia; Yong-En Gu; Yi-Bei Zang; Zi-Song Zhou; Zhao-Zhao Tian
Bone marrow blasts- and modified EASIX-guided risk stratification for coagulopathy and outcomes after CAR-T therapy in relapsed/refractory B-ALL

骨髓原始细胞百分比和改良EASIX指导的凝血功能障碍及CAR-T治疗后B-ALL复发/难治性患者的风险分层与结局

Thrombosis Research
IF3.4
2025-11-030
PRE
Yingying Li; Jiachen Liu; Lili Luo; Lijuan Zhou; Zhong Wu; Wei Sang; Huiwen Jiang; Jingming Wang; Xindi Wang; Peiru Li; Zhaozhao Chen; Jinhui Shu; Wenjing Luo; Yu Hu; YuHua Li; Heng Mei
BTK Inhibitor Synergizes With CD19-Targeted Chimeric Antigen Receptor-T Cells in Patients With Relapsed or Refractory B-Cell Lymphoma: An Open-Label Pragmatic Clinical Trial

BTK抑制剂与CD19靶向嵌合抗原受体T细胞在复发或难治性B细胞淋巴瘤患者中协同作用：一项开放标签实用型临床试验

CANCER MEDICINE
IF3.1
2025-10-230
OAAI
Luo, Wenjing; Zhang, Yinqiang; Li, Chenggong; Xu, Jia; Wu, Zhuolin; Wang, Xindi; Kang, Yun; Liao, Danying; Kou, Haiming; Xie, Wei; Xiong, Wei; Deng, Jun; Mei, Heng; Hu, Yu
Hetrombopag for Patients with Persistent Primary Immune Thrombocytopenia: A Post-hoc Analysis of A multicenter, Randomized Phase Ⅲ Trial

Hetrombopag for Patients with Persistent Primary Immune Thrombocytopenia: 一项多中心、随机Ⅲ期试验的后续分析

Research and Practice in Thrombosis and Haemostasis
IF3.4
2025-10-070
OAAI
Heng Mei; Xiaofan Liu; Yan Li; Hu Zhou; Ying Feng; Guangxun Gao; Peng Cheng; Ruibin Huang; Linhua Yang; Jianda Hu; Ming Hou; Yazhou Yao; Li Liu; Yi Wang; Depei Wu; Xuliang Shen; Jie Jin; Jianmin Luo; Yun Zeng; Xin Zhou; Ruixiang Xia; Zhongxing Jiang; Yuansong Bai; Liping Wang; Ting Niu; Renchi Yang; Yu Hu
Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma

II期研究：zevorcabtagene autoleucel，一种靶向BCMA的全人源CAR T细胞疗法，在复发/难治性多发性骨髓瘤患者中的应用

Experimental Hematology & Oncology
IF13.5
2025-10-020
OAAI
Wenming Chen; Chengcheng Fu; Baijun Fang; Aibin Liang; Zhongjun Xia; Yanjuan He; Jin Lu; Hui Liu; Ming Hou; Zhen Cai; Wei Yang; Siguo Hao; Songfu Jiang; Hongmei Jing; Jing Liu; Xin Du; Rong Fu; Heng Mei; Zunmin Zhu; Yanli Yang; Hong Liu; Xingxing Meng; Nishanthan Rajakumaraswamy; Daijing Yuan; Huamao Wang; Zonghai Li

研究方向

暂未获取到该数据
Y
Yu Hu
H 指数:79论文数:779被引数:3.3万
C
Chenggong Li
H 指数:15论文数:90被引数:1,065
H
Huiwen Jiang
H 指数:14论文数:66被引数:1,085
W
Wenjing Luo
H 指数:16论文数:122被引数:1,052
M
Ming Hou
H 指数:50论文数:398被引数:9,695
Y
Yinqiang Zhang
H 指数:16论文数:97被引数:896
D
Danying Liao
H 指数:10论文数:35被引数:1,401
H
Huafang Wang
H 指数:28论文数:202被引数:3,046
R
Ruibin Huang
H 指数:20论文数:76被引数:1,054
M
Mengyi Du
H 指数:13论文数:66被引数:636